1
|
Pattison AM, Merlino DJ, Blomain ES and
Waldman SA: Guanylyl cyclase C signaling axis and colon cancer
prevention. World J Gastroenterol. 22:8070–8077. 2016. View Article : Google Scholar : PubMed/NCBI
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
3
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Frampton M and Houlston RS: Modeling the
prevention of colorectal cancer from the combined impact of host
and behavioral risk factors. Genet Med. 19:314–321. 2017.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Das M, Ithychanda S, Qin J and Plow EF:
Mechanisms of talin-dependent integrin signaling and crosstalk.
Biochim Biophys Acta. 1838:579–588. 2014. View Article : Google Scholar : PubMed/NCBI
|
6
|
Calderwood DA and Ginsberg MH: Talin
forges the links between integrins and actin. Nat Cell Biol.
5:694–697. 2003. View Article : Google Scholar : PubMed/NCBI
|
7
|
Hu X, Jing C, Xu X, Nakazawa N, Cornish
VW, Margadant FM and Sheetz MP: Cooperative vinculin binding to
talin mapped by time-resolved super resolution microscopy. Nano
Lett. 16:4062–4068. 2016. View Article : Google Scholar : PubMed/NCBI
|
8
|
Giancotti FG and Ruoslahti E: Integrin
signaling. Science. 285:1028–1032. 1999. View Article : Google Scholar : PubMed/NCBI
|
9
|
Klapholz B and Brown NH: Talin-the master
of integrin adhesions. J Cell Sci. 130:2435–2446. 2017. View Article : Google Scholar : PubMed/NCBI
|
10
|
Becam IE, Tanentzapf G, Lepesant JA, Brown
NH and Huynh JR: Integrin-independent repression of cadherin
transcription by talin during axis formation in Drosophila. Nat
Cell Biol. 7:510–516. 2005. View
Article : Google Scholar : PubMed/NCBI
|
11
|
Zhang JL, Qian YB, Zhu LX and Xiong QR:
Talin1, a valuable marker for diagnosis and prognostic assessment
of human hepatocelluar carcinomas. Asian Pac J Cancer Prev.
12:3265–3269. 2011.PubMed/NCBI
|
12
|
Sakamoto S and Kyprianou N: Targeting
anoikis resistance in prostate cancer metastasis. Mol Aspects Med.
31:205–214. 2010. View Article : Google Scholar : PubMed/NCBI
|
13
|
Lai MT, Hua CH, Tsai MH, Wan L, Lin YJ,
Chen CM, Chiu IW, Chan C, Tsai FJ and Jinn-Chyuan Sheu J: Talin-1
overexpression defines high risk for aggressive oral squamous cell
carcinoma and promotes cancer metastasis. J Pathol. 224:367–376.
2011. View Article : Google Scholar : PubMed/NCBI
|
14
|
Chen P, Zheng X, Zhou Y, Xu Y, Zhu L and
Qian Y: Talin-1 interaction network promotes hepatocellular
carcinoma progression. J Cell Sci. 8:13003–13014. 2017.
|
15
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
16
|
Huang C, Yang G, Jiang T, Zhu G, Li H and
Qiu Z: The effects and mechanisms of blockage of STAT3 signaling
pathway on IL-6 inducing EMT in human pancreatic cancer cells in
vitro. Neoplasma. 58:396–405. 2011. View Article : Google Scholar : PubMed/NCBI
|
17
|
Chang KC, Wu MH, Jones D, Chen FF and
Tseng YL: Activation of STAT3 in thymic epithelial tumours
correlates with tumour type and clinical behaviour. J Pathol.
210:224–233. 2006. View Article : Google Scholar : PubMed/NCBI
|
18
|
Kusaba T, Nakayama T, Yamazumi K, Yakata
Y, Yoshizaki A, Nagayasu T and Sekine I: Expression of p-STAT3 in
human colorectal adenocarcinoma and adenoma; correlation with
clinicopathological factors. J Clin Pathol. 58:833–838. 2005.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Grandis JR, Drenning S, Zeng Q, Watkins
SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y and Kim JD:
Constitutive activation of Stat3 signaling abrogates apoptosis in
squamous cell carcinogenesis in vivo. Proc Natl Acad Sci
USA. 97:4227–4232. 2000. View Article : Google Scholar : PubMed/NCBI
|
20
|
Dhir R, Ni Z, Lou W, DeMiguel F, Grandis
JR and Gao AC: Stat3 activation in prostatic carcinomas. Prostate.
51:241–246. 2002. View Article : Google Scholar : PubMed/NCBI
|
21
|
Scholz A, Heinze S, Detjen KM, Peters M,
Welzel M, Hauff P, Schirner M, Wiedenmann B and Rosewicz S:
Activated signal transducer and activator of transcription 3
(STAT3) supports the malignant phenotype of human pancreatic
cancer. Gastroenterology. 125:891–905. 2003. View Article : Google Scholar : PubMed/NCBI
|
22
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
24
|
Garbers C, Hermanns HM, Schaper F,
Muller-Newen G, Grotzinger J, Rose-John S and Scheller J:
Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine
Growth Factor Rev. 23:85–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
25
|
Middleton K, Jones J, Lwin Z and Coward
JI: Interleukin-6: An angiogenic target in solid tumours. Crit Rev
Oncol Hematol. 89:129–139. 2014. View Article : Google Scholar : PubMed/NCBI
|
26
|
Xu Q, Briggs J, Park S, Niu G, Kortylewski
M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza G, et al:
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by
multiple oncogenic growth signaling pathways. Oncogene.
24:5552–5560. 2005. View Article : Google Scholar : PubMed/NCBI
|
27
|
Jung JE, Lee HG, Cho IH, Chung DH, Yoon
SH, Yang YM, Lee JW, Choi S, Park JW, Ye SK and Chung MH: STAT3 is
a potential modulator of HIF-1-mediated VEGF expression in human
renal carcinoma cells. FASEB J. 19:1296–1298. 2005. View Article : Google Scholar : PubMed/NCBI
|
28
|
Paleri V, Mehanna H and Wight RG: TNM
classification of malignant tumours 7th edition: What's new for
head and neck? Clin Otolaryngol. 35:270–272. 2010. View Article : Google Scholar : PubMed/NCBI
|
29
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: Application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
30
|
Wu Z, Li X, Sunkara M, Spearman H, Morris
AJ and Huang C: PIPKIγ regulates focal adhesion dynamics and colon
cancer cell invasion. PLoS One. 6:e247752011. View Article : Google Scholar : PubMed/NCBI
|
31
|
Liu B, Pang B, Hou X, Fan H, Liang N,
Zheng S, Feng B, Liu W, Guo H, Xu S and Pang Q: Expression of
high-mobility group AT-hook protein 2 and its prognostic
significance in malignant gliomas. Hum Pathol. 45:1752–1758. 2014.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Xu N, Chen HJ, Chen SH, Xue XY, Chen H,
Zheng QS, Wei Y, Li XD, Huang JB, Cai H and Sun XL: Upregulation of
Talin-1 expression associates with advanced pathological features
and predicts lymph node metastases and biochemical recurrence of
prostate cancer. Medicine. 95:e43262016. View Article : Google Scholar : PubMed/NCBI
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Avalle L, Camporeale A, Camperi A and Poli
V: STAT3 in cancer: A double edged sword. Cytokine. 98:42–50. 2017.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Hodge DR, Hurt EM and Farrar WL: The role
of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer.
41:2502–2512. 2005. View Article : Google Scholar : PubMed/NCBI
|
36
|
Critchley DR: Biochemical and structural
properties of the integrin-associated cytoskeletal protein talin.
Annu Rev Biophys. 38:235–254. 2009. View Article : Google Scholar : PubMed/NCBI
|
37
|
Anthis NJ, Wegener KL, Ye F, Kim C, Goult
BT, Lowe ED, Vakonakis I, Bate N, Critchley DR, Ginsberg MH and
Campbell ID: The structure of an integrin/talin complex reveals the
basis of inside-out signal transduction. EMBO J. 28:3623–3632.
2009. View Article : Google Scholar : PubMed/NCBI
|
38
|
Kang W, Kim SH, Cho HJ, Jin J, Lee J, Joo
KM and Nam DH: Talin1 targeting potentiates anti-angiogenic therapy
by attenuating invasion and stem-like features of glioblastoma
multiforme. Oncotarget. 6:27239–27251. 2015. View Article : Google Scholar : PubMed/NCBI
|
39
|
Muto M, Mori M, Hiwasa T, Takiguchi M,
Iwadate Y, Uzawa A, Uchida T, Masuda H, Sugimoto K and Kuwabara S:
Novel serum autoantibodies against talin1 in multiple sclerosis:
Possible pathogenetic roles of the antibodies. J Neuroimmunol.
284:30–36. 2015. View Article : Google Scholar : PubMed/NCBI
|
40
|
Singel SM, Cornelius C, Batten K, Fasciani
G, Wright WE, Lum L and Shay JW: A targeted RNAi screen of the
breast cancer genome identifies KIF14 and TLN1 as genes that
modulate docetaxel chemosensitivity in triple-negative breast
cancer. Clin Cancer Res. 19:2061–2070. 2013. View Article : Google Scholar : PubMed/NCBI
|
41
|
Sen S, Ng WP and Kumar S: Contributions of
talin-1 to glioma cell-matrix tensional homeostasis. J R Soc
Interface. 9:1311–1317. 2012. View Article : Google Scholar : PubMed/NCBI
|
42
|
Kanamori H, Kawakami T, Effendi K,
Yamazaki K, Mori T, Ebinuma H, Masugi Y, Du W, Nagasaka K, Ogiwara
A, et al: Identification by differential tissue proteome analysis
of talin-1 as a novel molecular marker of progression of
hepatocellular carcinoma. Oncology. 80:406–415. 2011. View Article : Google Scholar : PubMed/NCBI
|
43
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
44
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
45
|
Kang Y and Massague J:
Epithelial-mesenchymal transitions: Twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
46
|
Onder TT, Gupta PB, Mani SA, Yang J,
Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis
via multiple downstream transcriptional pathways. Cancer Res.
68:3645–3654. 2008. View Article : Google Scholar : PubMed/NCBI
|
47
|
Grivennikov SI and Karin M: Inflammatory
cytokines in cancer: Tumour necrosis factor and interleukin 6 take
the stage. Ann Rheum Dis. 70 (Suppl 1):i104–i108. 2011. View Article : Google Scholar : PubMed/NCBI
|
48
|
Elinav E, Nowarski R, Thaiss CA, Hu B, Jin
C and Flavell RA: Inflammation-induced cancer: Crosstalk between
tumours, immune cells and microorganisms. Nat Rev Cancer.
13:759–771. 2013. View Article : Google Scholar : PubMed/NCBI
|
49
|
Eldesoky A, Shouma A, Mosaad Y and
Elhawary A: Clinical relevance of serum vascular endothelial growth
factor and interleukin-6 in patients with colorectal cancer. Saudi
J Gastroenterol. 17:170–173. 2011. View Article : Google Scholar : PubMed/NCBI
|